dolutegravir sodium; rilpivirine hydrochloride - Profile

What are the generic sources for dolutegravir sodium; rilpivirine hydrochloride and what is the scope of freedom to operate?

Dolutegravir sodium; rilpivirine hydrochloride is the generic ingredient in one branded drug marketed by Viiv Hlthcare and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Dolutegravir sodium; rilpivirine hydrochloride has three hundred and twenty-two patent family members in fifty-one countries.

Summary for dolutegravir sodium; rilpivirine hydrochloride

International Patents:	322
US Patents:	4
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for dolutegravir sodium; rilpivirine hydrochloride

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for dolutegravir sodium; rilpivirine hydrochloride

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JULUCA	Tablets	dolutegravir sodium; rilpivirine hydrochloride	50 mg/25 mg	210192	1	2019-11-19

US Patents and Regulatory Information for dolutegravir sodium; rilpivirine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	JULUCA	dolutegravir sodium; rilpivirine hydrochloride	TABLET;ORAL	210192-001	Nov 21, 2017		RX	Yes	Yes			Y	Y
Viiv Hlthcare	JULUCA	dolutegravir sodium; rilpivirine hydrochloride	TABLET;ORAL	210192-001	Nov 21, 2017		RX	Yes	Yes			Y
Viiv Hlthcare	JULUCA	dolutegravir sodium; rilpivirine hydrochloride	TABLET;ORAL	210192-001	Nov 21, 2017		RX	Yes	Yes					Y
Viiv Hlthcare	JULUCA	dolutegravir sodium; rilpivirine hydrochloride	TABLET;ORAL	210192-001	Nov 21, 2017		RX	Yes	Yes					Y

Expired US Patents for dolutegravir sodium; rilpivirine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viiv Hlthcare	JULUCA	dolutegravir sodium; rilpivirine hydrochloride	TABLET;ORAL	210192-001	Nov 21, 2017
Viiv Hlthcare	JULUCA	dolutegravir sodium; rilpivirine hydrochloride	TABLET;ORAL	210192-001	Nov 21, 2017
Viiv Hlthcare	JULUCA	dolutegravir sodium; rilpivirine hydrochloride	TABLET;ORAL	210192-001	Nov 21, 2017
Viiv Hlthcare	JULUCA	dolutegravir sodium; rilpivirine hydrochloride	TABLET;ORAL	210192-001	Nov 21, 2017
Viiv Hlthcare	JULUCA	dolutegravir sodium; rilpivirine hydrochloride	TABLET;ORAL	210192-001	Nov 21, 2017

International Patents for dolutegravir sodium; rilpivirine hydrochloride

Country	Patent Number	Title	Estimated Expiration
European Patent Office	3127542
European Patent Office	2527007	Dérivé de carbamoylpyridone polycyclique doté d'une activité inhibitrice de l'intégrase du VIH (Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity)
South Korea	101848819
China	110958883
Taiwan	201919586	Combination and uses and treatments thereof
Serbia	65183

Supplementary Protection Certificates for dolutegravir sodium; rilpivirine hydrochloride

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2465580	768	Finland
2465580	301109	Netherlands		PRODUCT NAME: CABOTEGRAVIR; REGISTRATION NO/DATE: EU/1/20/1481 20201217
3494972	LUC00346	Luxembourg		PRODUCT NAME: DOLUTEGRAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, Y COMPRIS LE DOLUTEGRAVIR SODIQUE, ET LAMIVUDINE; AUTHORISATION NUMBER AND DATE: EU/1/19/1370 20190703
1874117	C201430032	Spain		PRODUCT NAME: DOLUTEGRAVIR O UNA SAL O SOLVATO DEL MISMO FARMACEUTICAMENTE ACEPTABLE, INCLUIDA LA SAL SODICA DE DOLUTEGRAVIR.; NATIONAL AUTHORISATION NUMBER: EU/1/13/892; DATE OF AUTHORISATION: 20140116; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/892; DATE OF FIRST AUTHORISATION IN EEA: 20140116
2932970	LUC00090	Luxembourg		PRODUCT NAME: COMBINAISON COMPRENANT DU DOLUTEGRAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (PAR EXEMPLE LE DOLUTEGRAVIR SODIQUE) ET LA RILPIVIRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (PAR EXEMPLE LE CHLORHYDRATE DE RILPIVIRINE); AUTHORISATION NUMBER AND DATE: EU/1/18/1282 20180518
3494972	PA2024516	Lithuania		PRODUCT NAME: DOLUTEGRAVIRAS ARBA FARMACINIU POZIURIU PRIIMTINA DRUSKA, ISKAITANT DOLUTEGRAVIRO NATRIO DRUSKA IR LAMIVUDINA; REGISTRATION NO/DATE: EU/1/19/1370 20190701

Dolutegravir Sodium + Rilpivirine Hydrochloride: Investment Scenario and Fundamentals Analysis

Last updated: April 25, 2026

What is the product and why does it matter to investors?

Dolutegravir (DTG) is an integrase strand transfer inhibitor (INSTI). Rilpivirine (RPV) is a non-nucleoside reverse transcriptase inhibitor (NNRTI). The combination is used in HIV-1 treatment and is built on a high-bar clinical rationale: durable viral suppression, once-daily dosing, and an established safety and resistance framework for DTG- and RPV-based regimens.

For investment analysis, the combination is typically evaluated via:

• Patent duration and exclusivity tail risk by country.
• Competitive pressure from DTG-based and long-acting regimens.
• Unit economics driven by HIV market stability and payer access.
• Manufacturing scale and supply chain defensibility across two actives.

What is the addressable commercial market and how resilient is demand?

HIV remains a large chronic-treatment market with high clinical adherence expectations and payer-driven formulary design. In practice, demand resilience for DTG and RPV combinations depends less on acute seasonality and more on:

• Long-term regimen durability and resistance outcomes
• Formularies and treatment guidelines that lock in preferred first-line or switch options
• Generics entry timing for both molecules and fixed-dose combinations (FDCs)

In the near term, the combination competes on:

• Tolerability and dosing convenience
• Switch eligibility for patients suppressed on prior regimens
• Regimen simplicity versus multi-pill alternatives

Which products anchor current commercial reality?

From a fundamentals perspective, the investment framing for this specific pairing usually centers on FDC branding in HIV care pathways. The combination is used in fixed-dose or co-formulated settings in multiple markets, but the most direct investment lens is:

• The existence of an on-patent FDC product (DTG + RPV)
• The timeline for generic FDC or component equivalents
• Claim scope that blocks “substantially identical” compositions and processes

Key reference points for active ingredients and indication scope are in regulatory drug labeling and in the HIV treatment landscape that supports DTG and RPV use. Regulatory anchor sources include FDA labeling for DTG and RPV drug products and the FDA product pages for the listed actives. [1], [2], [3]

What do the patents typically cover (and where do investors get risk)?

In HIV combinations, patent portfolios usually separate into layers that matter for investor returns:

1. Composition of matter (DTG and RPV combinations, salts, and crystalline forms)
2. Formulation patents (fixed-dose combinations, tablet/crystal engineering, dissolution and stability)
3. Manufacturing process patents
4. Use patents (treatment regimens, dosing schedules, patient populations)
5. Polymorph or solid-state form patents

Investment risk concentrates in:

• Jurisdiction-specific claim strength at generic filing and pre-grant review timelines
• Ability to design around formulation patents with different excipients, process parameters, or solid state forms
• Salt and polymorph transitions that can reduce infringement leverage

Patent term management also matters. Investors should treat portfolio value as conditional on effective exclusivity in the highest-volume markets (U.S., EU5, Japan, key ROW).

How do the clinical and regulatory basics translate into reimbursement power?

Clinically, both actives are established in HIV regimens:

• DTG: INSTI with a high barrier to resistance
• RPV: NNRTI with regimen constraints tied to viral load and CD4 context in historical use

In reimbursement terms, payer acceptance is typically driven by:

• Guideline alignment for first-line and switch therapy
• Evidence of durable suppression in treated and suppressed patient populations
• Switching behavior from older NNRTI-based regimens

From an investment fundamentals standpoint, this means market uptake is more sensitive to:

• New competitors that disrupt regimen convenience (including long-acting options)
• Generic and biosimilar-like substitution analogs are not relevant here; however, small-molecule generics are direct pricing pressure catalysts

Regulatory documentation of DTG and RPV labeling supports an investor view of approved use and dosing constructs. [1], [2], [3]

What is the competitive landscape pressure, and what would change the economics?

Key competitive vectors:

• DTG-centered fixed-dose combinations and newer integrase-based FDCs
• NNRTI-based alternatives that replicate dosing convenience
• Long-acting injectable HIV regimens that compete for stable, suppressed patients

Economics shift when:

• Formularies re-rank preferred regimens for switch patients
• Generic entry reduces pricing and compresses margins
• Payer step therapy changes regimen eligibility

Investors should monitor:

• Generic launch timelines for DTG/RPV (and for any FDC authorized equivalents)
• Label expansions or restrictions that change who can use the regimen
• Claims that block design-around generic strategies (composition and formulation)

What is the patent and exclusivity strategy that typically determines valuation?

Even without asserting specific docket outcomes in this response, the valuation mechanism for the DTG + RPV combination usually follows a common investment pattern:

• The portfolio’s composition-of-matter and formulation exclusivity determines the hard stop for generic FDC products.
• Solid-state or polymorph claims determine whether partial design-around can still enter during the tail period.
• Process and use claims act as secondary layers that can slow entry even when composition claims are weaker or invalidated.

DTG and RPV each have long-running intellectual property landscapes as standalone actives and as combination partners across HIV therapies. The investment takeaway is that combo value is tied to the strength of FDC-specific claims versus generic substitution of components.

Is there any regulatory or legal structure that affects market entry cadence?

For HIV small molecules, the market entry cadence is driven by:

• Patent expiry and the state of the regulatory exclusivity landscape in each jurisdiction
• Generic filing and approval paths (bioequivalence for small molecules)
• Litigation outcomes around composition and formulation claims, which decide launch timing

In the U.S., the regulatory framework is anchored in FDA drug approval mechanics and labeling stability for these actives. [1], [2], [3]

Key investment scenario framing

Base case: portfolio strength holds through key markets

• Scenario logic: FDC-specific composition and formulation claims remain enforceable in core geographies.
• Value drivers: sustained demand from switch cohorts and first-line segments that follow guideline preferences.
• Margin profile: pricing power holds until generic FDC entry.

Downside: generic entry accelerates due to claim vulnerability

• Scenario logic: generic challenges succeed against FDC-specific claims, enabling earlier launch.
• Value drivers that break: loss of premium pricing and payer preference shifts.
• Margin profile: rapid compression after launch and increased contracting intensity.

Upside: incremental exclusivity through formulation/solid-state or new label eligibility

• Scenario logic: additional, enforceable formulation or solid-state layers protect against design-around.
• Value drivers: broader eligible populations and stable switching flows.

What are the fundamental checkpoints investors should map to cash flow?

1) Exclusivity tail by major geography

• U.S., EU5, Japan as the key margin centers
• Portfolio layers: composition, formulation, solid state, and method of use

2) Competitive switching and substitution

• DTG-based alternatives and NNRTI substitutes
• Long-acting competitors for stable patients

3) Pricing and contracting

• Post-generic pricing trajectory for HIV small molecules
• Payer formulary dynamics by line of therapy

4) Manufacturing and supply

• Capacity for high-purity APIs (DTG and RPV) and FDC tablet stability
• Cost structure resilience under generic competitive pressure

Where do investors get “proof” for safety and dosing reliability?

FDA labeling provides the authoritative dosing and safety reference points for the actives used in HIV treatment. Investors use labeling stability to forecast:

• Likely persistence of standard of care usage
• Risk of label restriction that would reduce eligible population
• Therapeutic window and adverse event profile that informs payer acceptance

Primary regulatory references for dosing and labeling context include:

• FDA labeling resources for dolutegravir and its product pages [1]
• FDA labeling resources for rilpivirine and its product pages [2]
• FDA product references for related HIV actives where needed for label context [3]

Key Takeaways

• Dolutegravir plus rilpivirine is an INSTI plus NNRTI HIV regimen pairing that supports durable suppression and payer acceptance through established labeling and clinical positioning.
• Investment value hinges on FDC-specific patent strength (composition, formulation, and solid-state layers) and how effectively the portfolio blocks generic entry in major markets.
• Downside risk is not demand collapse; it is margin compression driven by generic or alternative regimen substitution at the exclusivity tail.
• The most actionable fundamentals checkpoints are exclusivity tail mapping by geography, competitive substitution effects on switch cohorts, and post-launch pricing trajectory.

FAQs

1. What drives valuation most for DTG + RPV combinations?
   The enforceability of fixed-dose combination-specific claims (composition and formulation/solid-state) in core markets and the timing of generic entry.

2. How does competition typically impact this regimen’s economics?
   By reducing payer preference for switch or first-line use and by introducing lower-cost generic or alternative branded regimens, compressing pricing and margins.

3. What is the biggest risk to the base-case scenario?
   A successful design-around or invalidation that enables earlier generic FDC launches than expected.

4. What fundamentals matter most for revenue stability?
   Persistence of standard of care dosing, guideline-aligned patient switching, and stable reimbursement access through major geographies.

5. Where do investors monitor for timing signals?
   Patent expiry calendar in the U.S., EU5, and Japan; filings and litigation outcomes tied to FDC-specific claims; and payer formulary updates that shift regimen eligibility.

---

References (APA)

[1] U.S. Food and Drug Administration. (n.d.). Dolutegravir (drug information and labeling). FDA. https://www.accessdata.fda.gov
[2] U.S. Food and Drug Administration. (n.d.). Rilpivirine (drug information and labeling). FDA. https://www.accessdata.fda.gov
[3] U.S. Food and Drug Administration. (n.d.). HIV drug product information and labeling resources. FDA. https://www.accessdata.fda.gov